Research.
Without the Hype.

What it is

Retatrutide is an investigational peptide-based medicine designed to activate three receptors involved in metabolic regulation: GIP, GLP-1, and glucagon receptors. These pathways influence glucose regulation, appetite, energy intake, and energy metabolism.

What current research investigates

• Changes in body weight and measures of adiposity.
• Glycemic control and other metabolic outcomes.
• Cardiometabolic risk factors and outcomes in defined populations.
• Safety, tolerability, and dose-related adverse events.

Updated clinical evidence

Retatrutide has advanced into large Phase 3 clinical trials. These studies are investigating weight management, metabolic outcomes, and safety across defined populations. Results from individual trials should be evaluated according to their study design, endpoints, publication status, and regulatory review.

Evidence and limitations

Retatrutide remains investigational. Clinical trial material is manufactured and administered under controlled study conditions. It must not be equated with unapproved online products or materials with unverified identity, concentration, purity, sterility, or storage history.

Scientific references

• PubMed: Retatrutide clinical research and publications
• ClinicalTrials.gov: Retatrutide clinical studies

What it is

AOD-9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone. It was developed to investigate whether selected metabolic activities associated with growth hormone could be studied independently of its broader growth-promoting effects.

Mechanisms under investigation

Early experimental studies explored the relationship between AOD-9604 and lipid metabolism, including the mobilization and breakdown of stored fat. These investigations helped establish the compound as a subject of metabolic research, particularly in relation to obesity and adipose tissue.

Research areas

• Regulation of lipid metabolism and lipolysis.
• Adipose tissue signaling and metabolic activity.
• Body-weight outcomes in clinical investigations.
• Metabolic selectivity compared with intact growth hormone.
• Pharmacological characterization and tolerability.

Human clinical research

AOD-9604 underwent clinical investigation as a potential obesity treatment. Although earlier laboratory and animal findings generated scientific interest, human development did not establish consistent, clinically meaningful weight-loss efficacy.

This distinction illustrates an important principle in translational research: a compound may influence biological pathways under controlled experimental conditions without producing the anticipated clinical outcome in humans.

Research perspective

AOD-9604 remains relevant to investigations of peptide structure, metabolic signaling, and the relationship between growth hormone fragments and lipid regulation. Further clinical evidence would be required to establish additional therapeutic applications.

Scientific references

• PubMed: AOD-9604 research publications
• ClinicalTrials.gov: AOD-9604 clinical research

What it is

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It interacts with receptors in the anterior pituitary gland, stimulating the release of endogenous growth hormone and influencing downstream insulin-like growth factor 1 (IGF-1) signaling.

Mechanism of action

Growth hormone participates in numerous physiological processes, including lipid metabolism, tissue growth, and metabolic regulation. Tesamorelin acts upstream of growth hormone secretion rather than directly replacing growth hormone itself.

Research has examined how stimulation of this pathway affects visceral adipose tissue, metabolic markers, and related endocrine responses.

Research areas

• Visceral adipose tissue and abdominal fat distribution.
• Growth hormone and IGF-1 signaling.
• Changes in body composition.
• Hepatic fat and metabolic characteristics in selected populations.
• Glucose metabolism and endocrine responses.

Human clinical evidence

Tesamorelin has been evaluated in controlled human clinical studies, particularly among adults with HIV-associated excess abdominal visceral fat. These studies demonstrated reductions in visceral adipose tissue in the populations investigated.

Additional research has explored relationships between visceral fat reduction, liver fat, and metabolic outcomes. Results from these populations should not automatically be generalized to healthy individuals or unrelated conditions.

Scientific considerations

The growth hormone–IGF-1 axis affects several interconnected biological systems. Research involving tesamorelin therefore includes evaluation of glucose regulation, fluid balance, musculoskeletal symptoms, and changes in circulating IGF-1.

Research perspective

Tesamorelin provides a useful example of how targeted endocrine signaling can influence regional adipose tissue. Its clinical research also demonstrates the importance of distinguishing changes in visceral fat from overall body-weight loss.

Scientific references

• PubMed: Tesamorelin and visceral adipose tissue
• PubMed: Tesamorelin and hepatic fat research
• ClinicalTrials.gov: Tesamorelin studies

What it is

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone designed to influence the body's endogenous growth hormone signaling system.

The designation DAC refers to a Drug Affinity Complex, a chemical modification intended to extend the compound's duration of activity through interaction with circulating albumin.

Mechanism under investigation

CJC-1295 interacts with the growth hormone-releasing hormone receptor, stimulating pituitary growth hormone secretion and influencing circulating IGF-1 concentrations.

The DAC modification changes the compound's pharmacokinetic characteristics. Consequently, CJC-1295 with DAC and similarly named peptides without DAC should be evaluated as distinct research materials.

Research areas

• Growth hormone secretion and endocrine signaling.
• Circulating IGF-1 responses.
• Pharmacokinetics and duration of biological activity.
• Receptor-mediated endocrine regulation.
• Consequences of prolonged growth hormone pathway stimulation.

Human clinical research

Early human studies demonstrated sustained increases in circulating growth hormone and IGF-1 following administration of CJC-1295 with DAC.

These investigations contributed to understanding the pharmacology of longer-acting GHRH analogues. However, changes in hormone concentrations do not independently establish improvements in muscle development, exercise performance, recovery, or longevity.

Scientific considerations

Endocrine research must distinguish measurable hormonal responses from meaningful clinical outcomes. Longer exposure to a signaling compound may also introduce different pharmacological considerations than short-duration stimulation.

Research perspective

CJC-1295 with DAC remains a useful research subject for understanding sustained growth hormone-releasing hormone receptor activation and the relationship between peptide modification and biological duration.

Scientific references

• PubMed: CJC-1295, growth hormone, and IGF-1
• ClinicalTrials.gov: CJC-1295 studies

What it is

Ipamorelin is a synthetic pentapeptide investigated for its ability to stimulate growth hormone secretion through activation of the growth hormone secretagogue receptor, commonly known as GHS-R1a.

Mechanism under investigation

The GHS-R1a receptor is associated with ghrelin signaling and participates in physiological pathways involving growth hormone secretion, appetite regulation, and gastrointestinal function.

Ipamorelin has been studied for its growth hormone-releasing activity and receptor selectivity relative to certain other growth hormone secretagogues.

Research areas

• Growth hormone secretagogue receptor activation.
• Pituitary growth hormone secretion.
• Ghrelin-related physiological signaling.
• Gastrointestinal motility research.
• Pharmacokinetics and receptor selectivity.
• Endocrine responses and tolerability.

Preclinical and clinical evidence

Experimental studies have characterized ipamorelin's receptor activity and its effects on growth hormone release. Human investigations have also examined selected pharmacological and gastrointestinal outcomes.

The available evidence does not establish broad clinical benefits for muscle growth, athletic performance, accelerated recovery, or age-related changes in otherwise healthy individuals.

Scientific considerations

Growth hormone secretagogues may differ in receptor selectivity, pharmacokinetics, and downstream hormonal responses. Findings involving one compound should not automatically be transferred to another compound within the same general research category.

Research perspective

Ipamorelin contributes to research on ghrelin-receptor pharmacology and the regulation of endogenous growth hormone. Further controlled human studies would be necessary to establish additional clinically meaningful outcomes.

Scientific references

• PubMed: Ipamorelin and growth hormone research
• PubMed: Ipamorelin and gastrointestinal motility
• ClinicalTrials.gov: Ipamorelin research

What it is

SS-31, also known as elamipretide, is a synthetic tetrapeptide investigated for its interactions with mitochondrial membranes and their role in cellular energy production.

Unlike compounds that primarily influence hormone receptors, elamipretide is designed to interact with structures associated with the inner mitochondrial membrane.

Mechanism under investigation

Elamipretide interacts with cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane. Cardiolipin plays an important role in the organization and stability of proteins involved in mitochondrial energy production.

Experimental research has investigated whether this interaction can influence mitochondrial membrane organization, electron transport, and cellular responses to mitochondrial stress.

Research areas

• Mitochondrial membrane structure and cardiolipin interactions.
• Electron transport chain organization and efficiency.
• Cellular ATP production and energy metabolism.
• Oxidative stress and mitochondrial dysfunction.
• Mitochondrial disorders and selected muscle-related outcomes.
• Cardiac, skeletal muscle, and metabolic tissue research.

Preclinical evidence

Laboratory and animal studies have explored elamipretide in models involving mitochondrial dysfunction, tissue injury, and altered cellular energy metabolism.

Some experimental findings suggest changes in mitochondrial function and tissue responses under specific research conditions. These findings remain dependent on the experimental model, treatment conditions, and outcomes measured.

Human clinical research

Elamipretide has been evaluated in human clinical studies involving mitochondrial disorders, including primary mitochondrial myopathy and Barth syndrome.

These studies have examined functional outcomes, exercise capacity, symptoms, and other disease-specific measures. Results have varied across studies and endpoints, demonstrating the complexity of translating mitochondrial mechanisms into clinical benefit.

Scientific considerations

Mitochondrial function involves numerous interconnected processes, including substrate utilization, electron transport, ATP synthesis, and cellular signaling. Improving a laboratory measure of mitochondrial activity does not necessarily establish improved physical performance or clinical outcomes in humans.

Research perspective

Elamipretide represents an important approach to mitochondrial research because it targets membrane-associated processes rather than relying solely on changes in cellular metabolism or hormonal signaling.

Scientific references

• PubMed: Elamipretide and cardiolipin research
• PubMed: Elamipretide and mitochondrial myopathy
• ClinicalTrials.gov: Elamipretide clinical studies

What it is

MOTS-C is a short peptide encoded within the mitochondrial genome. It belongs to a growing category of mitochondrial-derived peptides investigated for their possible roles in cellular communication, metabolic adaptation, and responses to physiological stress.

Mechanism under investigation

Experimental studies suggest that MOTS-C may influence metabolic signaling pathways associated with cellular energy balance. Research has examined relationships involving AMP-activated protein kinase (AMPK), metabolic stress responses, and the regulation of cellular metabolism.

Some studies have also investigated the movement of MOTS-C into the cell nucleus during metabolic stress and its potential involvement in the regulation of stress-responsive gene expression.

Research areas

• AMPK-associated metabolic signaling.
• Cellular adaptation to metabolic stress.
• Glucose metabolism and insulin sensitivity.
• Mitochondrial-to-nuclear communication.
• Exercise-related metabolic adaptation.
• Age-associated changes in metabolic regulation.

Preclinical evidence

Animal and cellular studies have investigated MOTS-C in models of metabolic dysfunction, aging, and physical activity.

Certain experimental findings suggest changes in metabolic regulation, insulin sensitivity, and exercise-related outcomes under specific conditions. These observations provide a foundation for further investigation but do not establish comparable effects in humans.

Human research

Human observational research has examined circulating MOTS-C levels, genetic variation, and possible associations with metabolic characteristics and aging.

Such findings are valuable for understanding biological relationships, but associations do not demonstrate that administering synthetic MOTS-C produces the same outcomes.

Scientific considerations

Endogenous mitochondrial-derived peptides and externally administered synthetic compounds must be evaluated separately. Differences in concentration, distribution, metabolism, and exposure may influence their biological effects.

Research perspective

MOTS-C illustrates the expanding understanding of mitochondria as participants in cellular communication, rather than solely as structures responsible for energy production.

Its greatest scientific relevance currently lies in the study of metabolic signaling, cellular stress, and mitochondrial-derived communication.

Scientific references

• PubMed: MOTS-C mitochondrial-derived peptide research
• PubMed: MOTS-C, AMPK, and metabolic signaling
• ClinicalTrials.gov: MOTS-C studies

What it is

Nicotinamide adenine dinucleotide, commonly abbreviated NAD+, is an essential coenzyme found in living cells. It participates in numerous biochemical reactions associated with cellular metabolism, energy production, and signaling.

NAD+ is not itself a peptide. It is included in this research directory because of its important relationship to mitochondrial biology and cellular metabolic function.

Role in cellular energy metabolism

NAD+ participates in oxidation-reduction reactions by accepting electrons and becoming NADH. The NAD+/NADH relationship is central to metabolic processes including glycolysis, the citric acid cycle, and mitochondrial oxidative phosphorylation.

Through these processes, NAD+ helps connect nutrient metabolism with the biochemical systems responsible for cellular ATP production.

Role in cellular signaling

In addition to its metabolic functions, NAD+ serves as a substrate for enzymes involved in cellular signaling and maintenance.

These include sirtuins, poly(ADP-ribose) polymerases (PARPs), and other NAD+-consuming enzymes associated with stress responses, DNA repair, and cellular regulation.

Research areas

• Cellular redox balance and energy metabolism.
• Mitochondrial oxidative phosphorylation.
• Sirtuin-associated cellular signaling.
• DNA damage responses and PARP activity.
• Age-associated changes in NAD+ metabolism.
• NAD+ biosynthesis and salvage pathways.
• Metabolic responses to NAD+ precursor supplementation.

Preclinical research

Experimental studies have examined how changes in NAD+ availability influence metabolic regulation, mitochondrial function, and cellular stress responses.

Animal studies involving NAD+ precursors have reported changes in selected metabolic and physiological outcomes. However, the results vary according to the experimental model, precursor, dose, and biological endpoint.

Human clinical research

Human studies have investigated NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

Some clinical studies demonstrate increases in measured NAD-related metabolites following precursor supplementation. Whether these biochemical changes consistently translate into meaningful improvements in physical function, metabolic health, or age-related outcomes remains an active research question.

Direct NAD+ versus NAD+ precursors

Direct NAD+ administration and supplementation with NAD+ precursors are different research approaches.

Their absorption, distribution, metabolism, cellular uptake, and clinical evidence cannot be assumed to be interchangeable. Findings from oral NR or NMN studies do not automatically establish the effects of injectable or intravenous NAD+.

Scientific considerations

NAD+ metabolism is regulated by multiple pathways, including synthesis, recycling, and enzymatic consumption.

Changes in blood NAD-related measurements may not accurately represent NAD+ availability within every tissue or cellular compartment.

Research perspective

NAD+ occupies a central position in the relationship between cellular energy metabolism and biological signaling.

Research into NAD+ continues to provide important insights into mitochondrial biology, metabolic regulation, cellular maintenance, and age-associated physiology.

Scientific references

• PubMed: NAD+ metabolism and mitochondrial biology
• PubMed: Nicotinamide riboside human clinical research
• PubMed: Nicotinamide mononucleotide human studies
• ClinicalTrials.gov: NAD metabolism research

What it is

FOXO4-DRI is an experimental peptide developed to investigate cellular senescence and the mechanisms that allow certain senescent cells to resist programmed cell death.

Cellular senescence is a biological state in which cells undergo a generally stable withdrawal from the cell cycle while remaining metabolically active.

Senescence can serve protective functions, including limiting the proliferation of damaged cells. However, persistent accumulation of some senescent cell populations may contribute to chronic inflammation and impaired tissue function.

Mechanism under investigation

FOXO4 is a transcription factor belonging to the forkhead box O family. Experimental research has identified interactions between FOXO4 and the tumor-suppressor protein p53 in certain senescent cells.

FOXO4-DRI was designed to interfere with this protein-protein interaction. The peptide uses a D-retro-inverso configuration intended to alter its molecular stability and biological characteristics.

In experimental models, disruption of FOXO4-p53 interactions has promoted p53-associated apoptosis in selected senescent cell populations.

Research areas

• Cellular senescence and apoptosis.
• FOXO4-p53 protein interactions.
• Senescence-associated secretory phenotype (SASP).
• Cellular responses to accumulated DNA damage.
• Tissue homeostasis during biological aging.
• Experimental approaches to selective senescent-cell elimination.

Foundational preclinical research

A landmark study published in Cell in 2017 investigated a FOXO4-derived peptide designed to disrupt the interaction between FOXO4 and p53.

Researchers observed selective reductions in the viability of certain senescent cells under laboratory conditions. In mouse models of accelerated and natural aging, the experimental approach was associated with improvements in selected measures of tissue function.

These findings helped establish FOXO4-p53 interactions as a subject of senolytic research, but the results remain specific to the experimental systems studied.

Current scientific questions

Further research is needed to determine how selectively FOXO4-DRI acts across different tissues and senescent-cell populations.

Important unanswered questions include tissue distribution, intracellular delivery, pharmacokinetics, repeated exposure, and possible effects on normal p53-dependent cellular functions.

Human clinical evidence

Published evidence supporting FOXO4-DRI remains predominantly laboratory and animal-based. Controlled human clinical trials have not established its efficacy for age-related conditions or longevity.

Research perspective

FOXO4-DRI represents a mechanistically distinctive approach to senescence research because it investigates the survival pathways of senescent cells rather than simply attempting to modify metabolic or inflammatory signaling.

Its scientific importance lies in advancing understanding of FOXO4-p53 interactions, selective apoptosis, and the complex biological roles of cellular senescence.

Scientific references

• Baar et al. (2017): Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging — Cell
• Full-text research: FOXO4-p53 interactions and experimental senescent-cell elimination
• PubMed: Additional FOXO4-DRI and cellular senescence research

What it is

GLOW is a multi-ingredient research formulation associated with scientific interest in tissue remodeling, extracellular matrix biology, and cellular repair mechanisms.

The term GLOW describes a formulation rather than a single universally standardized peptide molecule. Its scientific interpretation therefore depends on the exact ingredients, their chemical identities, and their respective quantities.

Research areas

• Cellular signaling associated with tissue remodeling.
• Extracellular matrix organization and collagen biology.
• Experimental wound-healing mechanisms.
• Inflammatory signaling during tissue repair.
• Angiogenesis and vascular responses in experimental models.
• Interactions between multiple research compounds.

Individual ingredient research

Compounds commonly discussed in tissue-repair peptide research include GHK-Cu, BPC-157, and thymosin beta-4-related peptides.

GHK-Cu is a copper-binding tripeptide investigated for its relationships with extracellular matrix regulation, collagen-associated processes, and tissue remodeling.

BPC-157 has been investigated primarily in preclinical models involving tissue injury, gastrointestinal biology, and inflammatory responses.

Thymosin beta-4 and related peptide fragments have been studied in connection with actin regulation, cell migration, and tissue repair mechanisms.

Research involving combinations

Combining biologically active research compounds introduces questions that cannot be answered by studying each ingredient independently.

These include possible changes in chemical stability, molecular interactions, biological activity, and the interpretation of experimental outcomes.

Evidence involving an individual ingredient does not establish that a finished combination produces equivalent, additive, or synergistic effects.

Formulation-specific considerations

Meaningful scientific evaluation of a GLOW formulation requires confirmation of its exact ingredient composition, concentration, identity, and analytical characteristics.

Formulations marketed under the same general name may differ between suppliers. Published findings involving one composition should not automatically be applied to another.

Research perspective

GLOW is best understood as a formulation-level research subject involving multiple biological pathways associated with tissue organization and repair.

Its scientific value depends on careful distinction between established ingredient-specific mechanisms, preclinical observations, and direct evidence involving the complete formulation.

Scientific references

• PubMed: GHK-Cu and extracellular matrix research
• PubMed: BPC-157 and experimental tissue repair
• PubMed: Thymosin beta-4 and wound-healing research

What it is

KLOW is a multi-ingredient research formulation intended to be examined as a defined combination of peptide-related research compounds.

As with other named research combinations, KLOW should not be treated as a single, universally standardized molecular entity.

The biological characteristics of a specific formulation depend on its verified ingredients, their quantities, and the analytical properties of the finished material.

Scientific framework

Research involving combinations of peptides may explore interactions between biological signaling pathways, cellular responses, and tissue-specific mechanisms.

However, a combination's scientific rationale must be distinguished from experimentally demonstrated effects.

Research areas

• Biological activity of individual formulation ingredients.
• Interactions between peptide-associated signaling pathways.
• Cellular and tissue-specific responses.
• Compound compatibility and formulation stability.
• Analytical verification of ingredient identity.
• Comparisons between individual compounds and complete combinations.

Ingredient-level evidence

Individual peptides may have published laboratory, animal, or human research describing particular molecular mechanisms.

The strength of that evidence varies substantially between compounds. A biological effect observed in one experimental model may not occur in another tissue, organism, or formulation.

Research findings should therefore be evaluated ingredient by ingredient before considering possible interactions within a combination.

Combination-level evidence

Direct investigation of a finished multi-ingredient formulation is necessary to characterize its combined biological activity.

A mixture may produce interactions that differ from the responses observed when its ingredients are studied separately.

Such interactions could be additive, antagonistic, or otherwise dependent on experimental conditions. Synergy should not be assumed without direct supporting evidence.

Analytical characterization

Scientific evaluation of KLOW requires attention to the identity and proportion of each constituent compound.

Relevant analytical considerations may include chromatographic separation, mass spectrometric identity testing, peptide purity, degradation products, and formulation stability.

The appropriate methods depend on the specific ingredients and intended experimental application.

Research perspective

KLOW illustrates the distinction between studying individual biologically active compounds and studying a defined multi-ingredient research formulation.

A scientifically meaningful assessment requires both reliable characterization of the material and direct evidence supporting claims about its combined activity.

Scientific references

• PubMed: Peptide combinations and biological interactions
• PubMed: Peptide identity and analytical characterization
• PubMed: Peptide formulation stability research